ReviewThe international journal of neuropsychopharmacology2015
Omics-Based Biomarkers: Application of Metabolomics in Neuropsychiatric Disorders.
Review in The international journal of neuropsychopharmacology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
53 citing papers in PubMed, 2 syntheses or guidelines pooled it, 117 citations in OpenAlex.
- Systematic Review and Meta-Analysis on MS-Based Proteomics Applied to Human Peripheral Fluids to Assess Potential Biomarkers of Bipolar Disorder.International journal of molecular sciences · 2022Pooled it
- An integrated meta-analysis of peripheral blood metabolites and biological functions in major depressive disorder.Molecular psychiatry · 2021Pooled it
- Untargeted plasma metabolomics identifies metabolite signatures associated with suicidality status in chronic schizophrenia.European archives of psychiatry and clinical neuroscience · 2026Article
- Mendelian-Randomization Study Reveals Causal Relationships Between Blood Metabolites and Psychiatric Disorders.Schizophrenia bulletin · 2026Article
- Longitudinal associations of cardiovascular-kidney-metabolic syndrome with midlife or late-life mental disorders and dementia, and the mediating role of metabolomic signature.Communications medicine · 2026Article
- Plasma Metabolic Characteristics and Potential Biomarker Combinations in Schizophrenia Patients With Tardive Dyskinesia.Schizophrenia bulletin · 2026Article
- Metabolic signatures and diagnostic models of ischemic stroke and its hypertensive subtype: a non-targeted metabolomics and machine learning.Frontiers in genetics · 2026Article
- Understanding stress through metabolomic and psychosocial lenses: Pathways to biomarker discovery.Journal of migration and health · 2026Article
- Metabolic Plasticity in Schizophrenia: Clinical Rehabilitation Meets LC-MS Metabolomics and Neurofeedback.International journal of molecular sciences · 2025Article
- Biomarkers of bipolar disorder in omics and neuroimaging.Journal of pharmaceutical analysis · 2025Review
- Validated metabolomic biomarkers in psychiatric disorders: a narrative review.Molecular medicine (Cambridge, Mass.) · 2025Review
- Dualistic Dynamics in Neuropsychiatry: From Monoaminergic Modulators to Multiscale Biomarker Maps.Biomedicines · 2025Article
- Metabolomic Insights into Attention Deficit Hyperactivity Disorder: A Scoping Review.Metabolites · 2025Review
- From Serendipity to Precision: Integrating AI, Multi-Omics, and Human-Specific Models for Personalized Neuropsychiatric Care.Biomedicines · 2025Review
- Identifying metabolic biomarkers and pathways in pulpitis: a metabolomic study using ultra-high-performance liquid chromatography/orbitrap mass spectrometry.Journal of applied oral science : revista FOB · 2025Article
- Advances in fenugreek breeding: novel genetic andFrontiers in plant science · 2025Review
- Serum Metabolites as Potential Markers and Predictors of Depression-like Behavior and Effective Fluoxetine Treatment in Chronically Socially Isolated Rats.Metabolites · 2024Article
- Integrative approach of omics and imaging data to discover new insights for understanding brain diseases.Brain communications · 2024Review
- Serum Metabolomics Analysis Revealed Metabolic Pathways Related to AECOPD Complicated with Anxiety and Depression.International journal of chronic obstructive pulmonary disease · 2024Observational
- Omics and Multi-Omics in IBD: No Integration, No Breakthroughs.International journal of molecular sciences · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
One of the major concerns of modern society is to identify putative biomarkers that serve as a valuable early diagnostic tool to identify a subset of patients with increased risk to develop neuropsychiatric disorders. Biomarker identification in neuropsychiatric disorders is proposed to offer a number of important benefits to patient well-being, including prediction of forthcoming disease, diagnostic precision, and a level of disease description that would guide treatment choice. Nowadays, the metabolomics approach has unlocked new possibilities in diagnostics of devastating disorders like neuropsychiatric disorders. Metabolomics-based technologies have the potential to map early biochemical changes in disease and hence provide an opportunity to develop predictive biomarkers that can be used as indicators of pathological abnormalities prior to development of clinical symptoms of neuropsychiatric disorders. This review highlights different -omics strategies for biomarker discovery in neuropsychiatric disorders. We also highlight initial outcomes from metabolomics studies in psychiatric disorders such as schizophrenia, bipolar disorder, and addictive disorders. This review will also present issues and challenges regarding the implementation of the metabolomics approach as a routine diagnostic tool in the clinical laboratory in context with neuropsychiatric disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.